Nicotine Dependence, Tobacco Use Cessation, Tobacco Use Disorder
Conditions
Keywords
Nicotine, Smoking, Smoking Cessation
Brief summary
The purpose of this study is to test whether Varenicline can help ambivalent smokers (those who are interested in quitting at some point in the future but have no current plans to quit) to reduce their smoking and eventually quit.
Detailed description
Many smokers want to quit but have no plans to do so in the near future. Recent studies indicate that helping such smokers reduce the number of cigarettes they smoke each day, try medications to see that medications can help control their cravings, can make it easier for them to try to quit. This study tests whether a new medication (generic name = varenicline; brand name = Chantix) can help smokers in these ways. The investigators will recruit 110 smokers in Vermont and 110 in Omaha, Nebraska, all of whom are interested in quitting some time in the future but have no current plans to quit. These smokers will be assigned by chance to receive either varenicline or a placebo. Neither the participants nor the scientists will know what the participants are receiving. Varenicline is a medication approved for smoking cessation in smokers who already have decided to quit. Varenicline both acts like nicotine to relieve craving and withdrawal when smokers try to quit and, importantly, also blocks the effects of nicotine from cigarettes. When smokers take varenicline and smoke, their cigarettes seem weaker and less beneficial. The investigators believe that making cigarettes less pleasing will make it easier for smokers to reduce, give them more control over their smoking, reduce their addiction to cigarettes, and make it easier for them to quit. After screening and giving consent, smokers will attend a first session to receive medication or placebo and to be instructed in how to use it to reduce their smoking. Smokers will be told they should use the medicine for at least 2 weeks and can use the medication for up to 2 months and, if they try to quit, they can receive an additional 3 months of medication after their quit date. Participants will be seen again at 2 weeks, 4 weeks and 2 months for brief help in reducing. After the first 2 months , they will be contacted by phone monthly for four more months. If participants are abstinent at 6 months they will be asked to return to provide a breath sample to verify abstinence. Participants will be asked to complete either written surveys or answer phone interviews and provide breath tests for which they will be reimbursed. The investigators will test, whether after 6 months, more smokers in the varenicline group tried to quit than in the placebo group.
Interventions
DRUGVarenicline
0.5 milligrams two times per day for 3 days, then 1.0 milligrams two times per day for an addition 11 days - 2 months
DRUGPlacebo
same as Varenicline arm
Sponsors
Pfizer
University of Vermont Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* At least 18 years old * Able to get to research lab in Burlington, Vermont or Omaha, Nebraska * Daily smoker * Smoke at least 8 cigarettes per day * No reduction in smoking in last 30 days * No intention to quit in the next 30 days * Never used Varenicline before * Not currently using smoking cessation medications or nicotine replacement therapy * Willing to use Varenicline for at least 2 weeks * Fluent in English
Exclusion criteria
* Cannot be currently pregnant or breastfeeding * Kidney disease * Frequent nausea * On certain medications for asthma and/or depression * Another household member in study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With a Quit Attempt | 6 months | A quit attempt was defined as a self-reported attempt to quit smoking on a given day reported on a Time Line Follow Back (TLFB) obtained at each visit for the first 2 months and via monthly phone calls during months 3-6. The TLFB collected information for each day since the previous visit/call on number of cigarettes smoked that day, whether medication (varenicline or placebo) was used that day, and whether a quit attempt occured that day. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 7 Day Point Prevalent Abstinence Verified by Breath Carbon Monoxide of Less Than 10 Parts Per Million | 6 months | 7 day point prevalent abstinence 6 months after enrolling in the study was determined by two steps: (1) A report of no days of smoking for the 7 days prior to the 6 month on the Time Line Follow Back obtained at a telephone call 6 months after enrollment; (2) Those who reported no smoking for the prior 7 days came to our lab for breath carbon monoxide (CO) measurement to confirm abstinence. Breath CO had to be less than 10 parts per million for the participant to be classified as abstinent. |
Countries
United States
Participant flow
Pre-assignment details
Enrolled sample size of 220; 2 were excluded because found to be ineligible after enrollment
Participants by arm
| Arm | Count |
|---|---|
| Varenicline 2 milligrams varenicline once per day for 2-8 weeks | 107 |
| Placebo Placebo once per day for 2-8 weeks | 111 |
| Total | 218 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lost to Follow-up | 45 | 50 |
Baseline characteristics
| Characteristic | Varenicline | Placebo | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 8 Participants | 5 Participants | 13 Participants |
| Age, Categorical Between 18 and 65 years | 99 Participants | 106 Participants | 205 Participants |
| Age Continuous | 44 years STANDARD_DEVIATION 14 | 41 years STANDARD_DEVIATION 15 | 42 years STANDARD_DEVIATION 15 |
| Region of Enrollment United States | 107 participants | 111 participants | 218 participants |
| Sex/Gender, Customized Female | 42 participants | 47 participants | 89 participants |
| Sex/Gender, Customized Male | 64 participants | 63 participants | 127 participants |
| Sex/Gender, Customized Missing | 1 participants | 1 participants | 2 participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 107 | 0 / 111 |
Outcome results
Primary
Number of Participants With a Quit Attempt
A quit attempt was defined as a self-reported attempt to quit smoking on a given day reported on a Time Line Follow Back (TLFB) obtained at each visit for the first 2 months and via monthly phone calls during months 3-6. The TLFB collected information for each day since the previous visit/call on number of cigarettes smoked that day, whether medication (varenicline or placebo) was used that day, and whether a quit attempt occured that day.
Time frame: 6 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Varenicline | Number of Participants With a Quit Attempt | 55 participants |
| Placebo | Number of Participants With a Quit Attempt | 36 participants |
p-value: 0.0695% CI: [1, 2.9]Chi-squared
Secondary
7 Day Point Prevalent Abstinence Verified by Breath Carbon Monoxide of Less Than 10 Parts Per Million
7 day point prevalent abstinence 6 months after enrolling in the study was determined by two steps: (1) A report of no days of smoking for the 7 days prior to the 6 month on the Time Line Follow Back obtained at a telephone call 6 months after enrollment; (2) Those who reported no smoking for the prior 7 days came to our lab for breath carbon monoxide (CO) measurement to confirm abstinence. Breath CO had to be less than 10 parts per million for the participant to be classified as abstinent.
Time frame: 6 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Varenicline | 7 Day Point Prevalent Abstinence Verified by Breath Carbon Monoxide of Less Than 10 Parts Per Million | 15 participants |
| Placebo | 7 Day Point Prevalent Abstinence Verified by Breath Carbon Monoxide of Less Than 10 Parts Per Million | 8 participants |
p-value: 0.195% CI: [0.9, 5.2]Chi-squared